Leonard Zehr, Author at BioTuesdays

This Week's Feature

Spring Bank Pharma may expand R&D with potential COVID-19 agents

After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...

May 19, 2020

Features

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic...

May 12, 2020

Features

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Daxor’s (NYSE American:DXR) BVA-100 blood volume measurement device is helping to open a new front in the battle against COVID-19. “Optimal volume management and knowledge of capillary status is key to survivability...

April 28, 2020

Features

Dr. Doug Manion of Kleo Pharmaceuticals talks up new approach to treating multiple myeloma

As chairman and CEO of Kleo Pharmaceuticals, a private immuno-oncology company developing next-generation bispecific compounds designed to enhance the activity of biologics, Dr. Doug Manion has a distinguished pedigree...

April 7, 2020

Features

Bee Vectoring bringing nature’s solution to healthy crops

Using the natural pollination process of commercially-reared bees and biological products and controls, Bee Vectoring Technology International (TSXV, CVE:BEE; OTCQB:BEVVF) has developed a pest and disease solution for...

March 24, 2020

Features

Obalon developing retail strategy for its weight loss solution: a swallowable, gas-filled intragastric balloon

Obalon Therapeutics (NASDAQ:OBLN) is pivoting its business model to a retail strategy of company-managed clinics to deliver its Obalon Balloon System, a weight loss solution that is the first and only swallowable, gas...

March 17, 2020

Features

Diabeloop bringing innovation to Type 1 diabetes patients

Closely-held Diabeloop of Grenoble, France has developed an external Type 1 diabetes management system, known as DBLG1, that connects three components: a continuous glucose monitor, a patch-like insulin pump and an...

March 10, 2020

Features

Anixa Biosciences harnessing interactions between tumors and the immune system

Anixa Biosciences (NASDAQ:ANIX) is taking multiple approaches to fighting cancer, developing both a diagnostic and therapeutics, such as a cancer immunotherapy and vaccine, to overcome immuno-suppression. Anixa...

March 3, 2020

Features

Ocugen developing therapies for rare and underserved eye diseases

Ocugen (NASDAQ:OCGN) is taking a multi-pronged approach to ophthalmology with a diversified pipeline that includes a breakthrough modifier gene therapy platform, novel biologics and small molecules, targeting a broad...

February 25, 2020

Features

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Using its unique ATLAS proprietary technology platform, Genocea Biosciences (NASDAQ:GNCA) is developing cancer immunotherapies that direct the body’s own tumor-fighting T-cells to the most therapeutically relevant...

February 18, 2020

Author - Leonard Zehr

Spring Bank Pharma may expand R&D with potential COVID-19 agents

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Daxor targeting blood volume analysis to reduce mortality and ventilator use in ICU

Dr. Doug Manion of Kleo Pharmaceuticals talks up new approach to treating multiple myeloma

Bee Vectoring bringing nature’s solution to healthy crops

Obalon developing retail strategy for its weight loss solution: a swallowable, gas-filled intragastric balloon

Diabeloop bringing innovation to Type 1 diabetes patients

Anixa Biosciences harnessing interactions between tumors and the immune system

Ocugen developing therapies for rare and underserved eye diseases

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter